Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment.

Carles J, Chirivella I, Climent MA, Gallardo E, González del Alba A, Maroto JP, Mellado B, García del Muro FX.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S3-9. doi: 10.1007/s10555-012-9353-0. Review.

PMID:
22689342
2.

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.

Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, Grünwald V.

Eur J Cancer. 2012 May;48(7):1023-30. doi: 10.1016/j.ejca.2012.02.048. Epub 2012 Mar 20.

PMID:
22436979
3.

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN.

BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x.

4.

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S11-7. doi: 10.1007/s10555-012-9354-z. Review.

PMID:
22674353
5.

Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.

Neuzillet Y, Culine S, Patard JJ.

Int J Urol. 2009 Nov;16(11):855-61. doi: 10.1111/j.1442-2042.2009.02365.x. Epub 2009 Aug 10. Review.

6.

Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.

Oudard S, Elaidi RT.

Cancer Treat Rev. 2012 Dec;38(8):981-7. doi: 10.1016/j.ctrv.2011.12.009. Epub 2012 Jan 30. Review.

PMID:
22289686
7.

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.

Ainsworth NL, Lee JS, Eisen T.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. doi: 10.1586/era.09.144. Review.

PMID:
19954291
8.

Quality of life and supportive care for patients with metastatic renal cell carcinoma.

Lambea J, Hinojo C, Lainez N, Lázaro M, León L, Rodríguez A, Soto de Prado D, Esteban E.

Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S33-9. doi: 10.1007/s10555-012-9357-9. Review.

PMID:
22684341
9.

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.

Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY.

Urology. 2010 Aug;76(2):430-4. doi: 10.1016/j.urology.2009.12.031. Epub 2010 Mar 12.

PMID:
20223508
10.

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J.

Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24. Review.

PMID:
21704448
11.

Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.

Lam JS, Belldegrun AS, Figlin RA.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6304S-9S. Review.

12.

Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.

Wright I, Kapoor A.

Curr Opin Support Palliat Care. 2011 Sep;5(3):211-21. doi: 10.1097/SPC.0b013e3283490418. Review.

PMID:
21725244
13.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group.

Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.

PMID:
21803569
14.

Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.

Bex A, Gore M, Mulders P, Sternberg CN.

BJU Int. 2012 Nov;110(9):1289-300. doi: 10.1111/j.1464-410X.2012.11100.x. Epub 2012 Mar 30. Review.

15.

Targeted therapies in renal cell cancer: recent developments in imaging.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E.

Target Oncol. 2010 Jun;5(2):95-112. doi: 10.1007/s11523-010-0146-5. Epub 2010 Jul 14. Review.

16.

Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy.

Powles T, Albers P.

Clin Genitourin Cancer. 2012 Dec;10(4):213-8. doi: 10.1016/j.clgc.2012.06.002. Epub 2012 Aug 30. Review.

PMID:
22939100
17.

Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.

Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, Rini BI.

Cancer. 2012 Jul 1;118(13):3277-82. doi: 10.1002/cncr.26666. Epub 2011 Dec 2. Erratum in: Cancer. 2012 Nov 1;118(21):5448.

18.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group.

Cancer. 2010 Sep 15;116(18):4256-65. doi: 10.1002/cncr.25219.

19.

Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.

Kirchner H, Strumberg D, Bahl A, Overkamp F.

Expert Rev Anticancer Ther. 2010 Apr;10(4):585-96. doi: 10.1586/era.10.25. Review.

PMID:
20397923
20.

Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.

Casciano R, Chulikavit M, Di Lorenzo G, Liu Z, Baladi JF, Wang X, Robertson J, Garrison L.

Value Health. 2011 Sep-Oct;14(6):846-51. doi: 10.1016/j.jval.2011.04.008. Epub 2011 Jul 28.

Supplemental Content

Support Center